Zobrazeno 1 - 10
of 230
pro vyhledávání: '"Yvonne A. Efebera"'
Autor:
Tondre Buck, Monique A. Hartley-Brown, Yvonne A. Efebera, Carter P. Milner, Jeffrey A. Zonder, Paul G. Richardson, Taylor Salinardi, Megan S. Rice
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
Examination of the impact of race and ethnicity on multiple myeloma (MM) outcomes has yielded inconsistent results. This retrospective, real-world (RW) study describes patient, disease, and treatment characteristics (and associations with survival ou
Externí odkaz:
https://doaj.org/article/4f1f9c13d5ba430dba88d9086aeb624c
Autor:
Audrey M. Sigmund, Justin Jiang, Qiuhong Zhao, Patrick Elder, Don M. Benson, Sumithira Vasu, Samantha Jaglowski, Alice S. Mims, Hannah Choe, Karilyn Larkin, Jonathan E. Brammer, Sarah A. Wall, Nicole Grieselhuber, William Basem, Sam Penza, Yvonne A. Efebera, Nidhi Sharma
Publikováno v:
Frontiers in Hematology, Vol 2 (2023)
BackgroundAllogeneic stem cell transplant (allo-SCT) plays a key role in the treatment of patients with both acute myeloid leukemia (AML) and myelodysplastic (MDS). Outcomes of allo-SCT have improved with optimization of transplant practices. We soug
Externí odkaz:
https://doaj.org/article/c65f2ecfcdca40aaa0df82a9fc6077a5
Autor:
Enrique M. Ocio, Yvonne A. Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, María-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul G. Richardson, Stefan Norin, Jakob Obermüller, Nicolaas A. Bakker, Luděk Pour
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Melphalan flufenamide (melflufen), a first-in-class, alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen
Externí odkaz:
https://doaj.org/article/2fc23bce08c444d98389254c7b7873ab
Autor:
Enrique Maria Ocio San Miguel, Yvonne A. Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, Maria-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul Richardson, Stefan Norin, Jakob Obermüller, Nicolaas A. Bakker, Ludek Pour
Publikováno v:
HemaSphere, Vol 7, p e2842627 (2023)
Externí odkaz:
https://doaj.org/article/e8b2fb37406c41c09b0b8b4194d694ec
Autor:
Pooja Khandelwal, Vijaya Chaturvedi, Erika Owsley, Yvonne A. Efebera, Hannah Choe, Matthew Bostic, Prashanti Kumchala, Girish Rajgolikar, Parvathi Ranganathan, Ramiro Garzon, Kelly Lake, Bridget Litts, Alexandra Duell, Patrick Elder, Stella M. Davies, Adam Lane, Michael B. Jordan, Sumithra Vasu, Steven Devine, Rebecca A. Marsh
Publikováno v:
Transplantation Reports, Vol 7, Iss 3, Pp 100100- (2022)
Introduction: We conducted a prospective validation study at Cincinnati Children's Hospital Medical Center and Ohio State University Medical Center to test if absolute CD38 bright CD8+TEM cells > 30/µL would predict acute GVHD, similar to our pilot
Externí odkaz:
https://doaj.org/article/6ad48f022f3d4a8582460eb163004509
Autor:
Nidhi Sharma, Yvonne A. Efebera
Publikováno v:
Cancers, Vol 15, Iss 5, p 1354 (2023)
Over the last 10 to 20 years, there have been significant improvements in the fields of both autologous and allogenic transplantation [...]
Externí odkaz:
https://doaj.org/article/88ecffa99e084cb4bb54357f10c74161
Autor:
Audrey M. Sigmund, Qiuhong Zhao, Justin Jiang, Patrick Elder, Don M. Benson, Ashley Rosko, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Sumithira Vasu, Samantha Jaglowski, Alice Mims, Hannah Choe, Karilyn Larkin, Jonathan Brammer, Sarah Wall, Nicole Grieselhuber, Ayman Saad, Sam Penza, Yvonne A. Efebera, Nidhi Sharma
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAllogeneic hematopoietic stem cell transplant (allo-HCT) is a potential curative therapy for a variety of hematologic disorders. However, it requires highly specialized care that is only available at select centers across the country. Thus,
Externí odkaz:
https://doaj.org/article/b0662b685499476d8f81142d3146c296
Autor:
Justin Jiang, Audrey M. Sigmund, Qiuhong Zhao, Patrick Elder, Don M. Benson, Sumithira Vasu, Samantha Jaglowski, Alice Mims, Hannah Choe, Karilyn Larkin, Jonathan E. Brammer, Sarah Wall, Nicole Grieselhuber, Ayman Saad, Sam Penza, Yvonne A. Efebera, Nidhi Sharma
Publikováno v:
Cancers, Vol 14, Iss 22, p 5587 (2022)
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment for many hematological disorders, but is often complicated by relapse of the underlying disease, graft-versus-host disease (GVHD), and infectious compli
Externí odkaz:
https://doaj.org/article/22d11a81d6094281bc1e57ec8d3bf572
Autor:
Jordan Nunnelee, Francesca Cottini, Qiuhong Zhao, Muhammad Salman Faisal, Patrick Elder, Ashley Rosko, Naresh Bumma, Abdullah Khan, Elvira Umyarova, Srinivas Devarakonda, Don M. Benson, Yvonne A. Efebera, Nidhi Sharma
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 19, p 5794 (2022)
Maintenance therapy after autologous stem cell transplant (ASCT) in multiple myeloma (MM) is the standard treatment and recommended to be continued until disease progression. However, in the real world, patients discontinue treatment due to various r
Externí odkaz:
https://doaj.org/article/3d0abc7c18cb425482c860e9bfacdfac
Autor:
Francesca Cottini, Ying Huang, Nita Williams, Naresh Bumma, Abdullah M. Khan, Maria Chaudhry, Srinivas Devarakonda, Yvonne A. Efebera, Don M. Benson, Ashley E. Rosko
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat pati
Externí odkaz:
https://doaj.org/article/bd3cf06e2e61452e9e916a5d0e927d54